In vitro activity and time-kill curve analysis of sitafloxacin against a global panel of antimicrobial-resistant and multidrug-resistant Neisseria gonorrhoeae isolates.

Jönsson, Agnez; Foerster, Sunniva; Golparian, Daniel; Hamasuna, Ryoichi; Jacobsson, Susanne; Lindberg, Magnus; Jensen, Jörgen Skov; Ohnishi, Makoto; Unemo, Magnus (2018). In vitro activity and time-kill curve analysis of sitafloxacin against a global panel of antimicrobial-resistant and multidrug-resistant Neisseria gonorrhoeae isolates. Acta pathologica, microbiologica et immunologica Scandinavica : APMIS, 126(1), pp. 29-37. Wiley-Blackwell 10.1111/apm.12777

[img] Text
J-nsson_et_al-2018-APMIS.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (531kB) | Request a copy

Treatment of gonorrhoea is a challenge worldwide because of emergence of resistance in N. gonorrhoeae to all therapeutic antimicrobials available and novel antimicrobials are imperative. The newer-generation fluoroquinolone sitafloxacin, mostly used for respiratory tract infections in Japan, can have a high in vitro activity against gonococci. However, only a limited number of recent antimicrobial-resistant isolates from Japan have been examined. We investigated the sitafloxacin activity against a global gonococcal panel (250 isolates cultured in 1991-2013), including multidrug-resistant geographically, temporally and genetically diverse isolates, and performed time-kill curve analysis for sitafloxacin. The susceptibility to sitafloxacin (agar dilution) and seven additional therapeutic antimicrobials (Etest) was determined. Sitafloxacin was rapidly bactericidal, and the MIC range, MIC50 and MIC90 was ≤0.001-1, 0.125 and 0.25 mg/L, respectively. There was a high correlation between the MICs of sitafloxacin and ciprofloxacin; however, the MIC50 and MIC90 of sitafloxacin were 6-fold and >6-fold lower, respectively. Sitafloxacin might be an option for particularly dual antimicrobial therapy of gonorrhoea and for cases with ceftriaxone resistance or allergy. However, further in vitro and particularly in vivo evaluations of potential resistance, pharmacokinetics/pharmacodynamics and ideal dosing for gonorrhoea, as well as performance of randomized controlled clinical, trials are crucial.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Förster, Sunniva Marita

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0903-4641

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Tanya Karrer

Date Deposited:

09 Jan 2018 16:35

Last Modified:

23 Oct 2019 02:45

Publisher DOI:

10.1111/apm.12777

PubMed ID:

29154480

Uncontrolled Keywords:

gyrA Gonorrhoea bactericidal fluoroquinolone in vitro potency quinolone resistance-determining region time-kill curve analysis

BORIS DOI:

10.7892/boris.107535

URI:

https://boris.unibe.ch/id/eprint/107535

Actions (login required)

Edit item Edit item
Provide Feedback